A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Crossref DOI link: https://doi.org/10.1186/s12967-015-0460-x
Published Online: 2015-03-28
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Koneru, Mythili
O’Cearbhaill, Roisin
Pendharkar, Swati
Spriggs, David R
Brentjens, Renier J
License valid from 2015-03-28
Article History
Received: 10 December 2014
Accepted: 11 March 2015
First Online: 28 March 2015